Previous 10 | Next 10 |
Equillium is a clinical-stage biotech company treating severe autoimmune and inflammatory disorders. CEO Bruce Steel discusses primary drug itolizumab pivotal study. Alternative to short-term, high dose steroid therapies. For further details see: Equillium CEO Bruce Stee...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at ACR Convergence, the annual meeting of th...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23 rd Annual Global Investment Conference, takin...
Gainers: Trillium Therapeutics TRIL +189%. Vivos Therapeutics VVOS +49%. ABVC BioPharma (OTCQB:ABVC) +29%. Pixelworks (NASDAQ:PXLW) +25%. LightInTheBox (NYSE:LITB) +27%. Canoo GOEV +25%. City Office CIO +25%. Equillium (NASDAQ:EQ) +24%. Endo International plc (NASDAQ...
Analysis of our Type A systemic lupus erythematosus patients without lupus nephritis that had elevated baseline urine protein/creatinine and albumin/creatinine ratios demonstrated a mean decrease of 42% and 53% respectively by Day 57 following two doses of Itolizumab The Type ...
Announced positive topline results from the EQUATE study of itolizumab in first-line treatment of acute graft-versus-host disease Announced plans to initiate a Phase 3 pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Equillium, I...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021. Bruce Steel, Equ...
Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application On track to initiate study in Q4 2021 LA JOLLA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology com...
Equillium ([[EQ]] -9.5%) said its drug itolizumab showed rapid and durable response as an initial treatment for acute graft-versus-host-disease in an early stage study.The phase 1b trial, dubbed EQUATE, evaluated itolizumab, along with standard of care corticosteroids, as first-line...
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...